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Objective: An open-label, prospective, uncontrolled study created to investigate clinical 
response, serological changes and side effects in Greek patients with rheumatoid arthritis (RA), 
after B-cell depletion with rituximab.
Methods: Patients with high disease activity (disease activity score [DAS]-28   5.1) were 
selected for treatment with rituximab and received two infusions, 1 gr each, 2 weeks apart. Dif-
ferent disease parameters (visual analog scale, DAS-28, C-reactive protein [CRP], erythrocyte 
sedimentation rate, health assessment questionnaire, complement (C3), C4, rheumatoid factor 
[RF], anti-cyclic citrullinated peptide antibody [anti-CCP], swollen joint count, tender joint 
count, immunoglobulin M [IgM], IgG, IgA) were performed at base line, 2, 4, and 6 months 
post-treatment. Response was deﬁ  ned according to the American College of Rheumatology 
(ACR) criteria.
Results: Seventeen patients received therapy. Treatment led to a reduction in various 
disease parameters. ACR20 was achieved in 41.11% of patients by week 8, 52.94% by 
week 16, and 82.35% by week 24. ACR50 was achieved in 5.88% by week 8, 41.17% by 
week 16, and 64.7% by week 24. ACR70 was achieved only by week 24 in 23.52% of patients. 
Statistical analysis has shown no differences in clinical response, between RF positive/negative 
patients, and anti-CCP-positive/negative patients, while decline of RF was better correlated with 
reduction of DAS-28 than with anti-CCP.
Conclusions: Rituximab is a well tolerated and effective treatment in RA. Response was not 
correlated to RF or anti-CCP positivity. Decline of RF was associated with clinical response 
and reduction of DAS-28 and CRP.
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Introduction
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that is estimated 
to affect 1% of the population worldwide, including all ethnic groups. The female/
male ratio is 3:1 (Sangha 2001; Lawrence and Haynes 2002; Lawrence et al 1998). 
It is characterized by symmetrical joint inﬂ  ammation, morning stiffness, and causes 
cartilage damage, bone erosions and deformity (Pincus et al 1984).
Rheumatoid arthritis is considered to be a nonorgan-speciﬁ  c autoimmune disease 
in which genetic, hormonal, immunologic and environmental factors play a role. 
Greek and North European RA patients have differences. Greek patients have less 
inﬂ  ammatory articular disease, fewer extra-articular manifestations, less severe joint 
damage, and a high frequency of Ro(SSA) antibodies linked to a higher prevalence 
of secondary Sjögren syndrome (Drosos and Moutsopoulos 1995; Drosos et al 1992). 
Furthermore, Greek RA patients are characterized with a lack of association with 
human leukocyte antigens (HLA) and only a weak association with HLA-DR1 and 
DR4 antigens (Boki et al 1992, 1993).
Over the last three decades there has been signiﬁ  cant improvement in patient 
outcomes. Even with advances in disease management, a population of patients with Biologics: Targets & Therapy 2008:2(4) 912
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refractory RA exists. In the clinical trials that led to approval of 
anti-tumor necrosis factor (TNF), 25%–40% of patients failed 
to achieve American College of Rheumatology (ACR)-20 
(Keystone et al 2004; Lipsky et al 2000; Weinblatt et al 2003; 
Feltelius et al 2005). Furthermore, a proportion of patients 
experience treatment-limiting-side effects, and 30%–40% 
of patients who respond to anti-TNF continue to experience 
residual level of disease activity (Conen et al 2006).
The need for treatment beyond TNF inhibitors in RA 
has become clear and rituximab is one such novel therapy. 
Rituximab is a genetically engineered chimerical monoclonal 
antibody, which binds to the antigen CD20, which regulates 
cell cycle initiation and differentiation. CD20 is found in 
normal and malignant pre-B, and mature B-lymphocytes. 
The antigen is absent in hematopoietic stem cells and plasma 
cells (Hoffman-La Roche 2000). B-cells are believed to play 
a role in the pathogenesis of RA and are associated to chronic 
synovitis (Benoist and Mathis 2000; Panagyi 2005). Edward 
and Cambridge (Edwards and Cambridge 2001) introduced 
the concept of human auto antibody-associated disease and 
‘self-perpetuating’ auto reactive B-cells. On the basis of 
this hypothesis, the ﬁ  rst published trials of rituximab in RA 
were set up and carried out at University College, London, 
UK (Edwards et al 1999). Beneﬁ  t was conﬁ  rmed by De Vita 
and colleagues (2002) and then further established in a large 
randomized trial (Edwards et al 2004).
Patients and methods
This is an open-label, clinical, observational, uncontrolled 
study which included seventeen Greek patients with refrac-
tory RA. All patients satisﬁ  ed the ACR diagnostic criteria for 
RA (Arnett et al 1988). The criterion for high disease activity 
that patients had to fulﬁ  ll in order to enter the study was the 
DAS-28 score which should be more than 5.1. Two patients 
were male and 15 were female. The median age was 53 years 
(range 27–78), and the median disease duration was 6 years 
(range 1–23). RF positive (positive : >20 IU/L) were 76%, and 
anti-cyclic citrullinated peptide antibody (anti-CCP) positive 
(positive: >15 IU/L) were 65%. The median number of pre-
treatment disease-modifying antirheumatic drugs (DMARDS) 
was three, the median number of pre-treatment biological 
factors was two and the mean/SD value of DAS-28 score was 
6.6 ± 0.78. The study was approved by the hospital ethics review 
board. Written consent was obtained from all patients.
Statistical analysis
A Student’s t-test was applied for comparison of the normal-
ized values. A P value   0.05 was considered signiﬁ  cant. 
The DAS28, health assessment questionnaire (HAQ) 20, 
C-reactive protein (CRP), and erythrocyte sedimentation rate 
(ESR) differences were calculated and the Mann-Whitney U test 
was used to compare them between rheumatioid factor (RF) 
(−)/RF (+) patients, and anti-CCP (−)/anti-CCP (+) patients.
Treatment
Patients continued their baseline DMARD treatment and other 
concomitant medications with no changes during follow-up of 
24 weeks. Rituximab was administrated as an intravenous infu-
sion of two dosages, 1000 mg each, with 2 weeks apart. Prior 
to each infusion, patients received paracetamol 600 mg (IV), 
Dimetindene (IV) and methylprednilosone 125 mg (IV) to 
attenuate possible infusion-related symptoms.
During infusions patients were closely observed for 
infusion related symptoms. However, there were no such 
symptoms necessitating divergence from the above schedule. 
No further rituximab infusions were administrated during the 
subsequent follow up period.
Clinical assessments
At start point a thorough history and physical examination 
was conducted and recorded, together with baseline demo-
graphic data.
For each patient at baseline and at weeks 8, 16, and 24 the 
number of tender and swollen joints (total number: 28), visual 
analogue scale (VAS) and the DAS-28, HAQ-20 scores were 
recorded. Blood samples were obtained at baseline and at fol-
low-up visits for assessment of laboratory measures including 
ESR, CRP, complement (C3) and C4 levels, immunoglobulin 
(Ig) A, IgM, and IgG levels, RF, and anti-CCP antibodies. Sam-
ples were processed and analyzed using standard techniques
Results
The baseline characteristics of the cohort are outlined in 
Table 1.
Table1 Baseline characteristics
Total Number of patients 17
Male/Female 2/15
Age (yrs): median (range) 53 (27–78)
Disease duration:  median (range) 6 (1–23)
RF positive n% 13 (76)
CCP positive n% 11 (65)
Number of pre-treatment DMARDs:  median (range) 3 (2–5)
Number of pre-treatment biological: median (range) 2 (1–3)
Prednisolone therapy: n (%) 14 (82)
Prednisolone dosage: median (range) 7, 5 (2, 5–15)Biologics: Targets & Therapy 2008:2(4) 913
Rituximab therapy in Greek patients with rheumatoid arthritis
Our patients had multi-DMARD and biologic-resistant 
RA. Apart from one patient with advanced pulmonary ﬁ  bro-
sis, none of the others had any major extra-articular disease. 
Follow up data were available at all 17 patients at 2, 4, and 
6 months. Changes in various parameters during follow up 
are shown in Table 2.
Fourteen patients presented clinical improvement as 
measured by the ACR criteria (Figure 1). Rituximab was 
effective in suppressing disease activity as evidenced by 
a statistical signiﬁ  cant reduction in DAS-28 and HAQ-20 
scores in 6 months follow up (Figure 2). Major improve-
ments were also seen in various parameters of the disease 
including CRP and ESR.
Primary outcome measure for this study was effi-
cacy as determined by ACR score. Secondary outcome 
measures were: DAS-28 and HAQ-20 scores and sero-
logical changes as determined by RF, anti-CCP, CRP, ESR. 
Auto antibodies levels decreased after rituximab therapy 
(Figure 3). RF levels revealed a statistically signiﬁ  cant decrease 
between the start point and 8th (p   0.01), 16th (p   0.01) 
and 24th (p   0.001) week. On the contrary, the differences 
of the anti-CCP values were not statistically significant 
(week 8 [p   0.1], week 16 [p   0.1], week 24 [p   0.1].
Total serum Igs decreased moderately during follow 
up. Their mean values remained within normal levels 
(Figure 4).
The DAS28, HAQ 20, CRP, and ESR differences 
between week 0 (start point) and weeks 8, 16, and 24, were 
compared for the RF (−) and RF (+) patients, and anti-CCP 
(−) and anti-CCP (+) patients. There were no signiﬁ  cant 
statistical differences in clinical response between these 
groups of patients.
Rituximab was well tolerated by all patients. There 
were no major adverse events during infusions, and no 
serious infections were observed in post-infusion period of 
six months. Concerning the minor side effects during the 
infusions we observed fever and chills in two patients and 
migraine in one; in the post-treatment period two patients 
experienced upper respiratory tract infections and another 
one tiredness and weakness.
Discussion
The results of this open label study showed substantial and 
persistent clinical beneﬁ  t in patients with resistant RA who 
have had inadequate response to multiple DMARD and 
biological treatment.
The responses seen in this open label study support 
the hypothesis that B cells are key contributors to the 
immunopathogenesis of RA through several potential 
mechanisms (Kim and Berek 2000; Gause and Berek 2004; 
Reparon-Schuijt et al 2001; Takemura et al 2001; Zhang and 
Bridges 2001; Shiokawa et al 2003). In our study the patients 
who were RF and anti-CCP seronegative demonstrated a 
similar treatment effect as those who were RF (+) and anti-
CCP (+) further suggesting that rituximab may act through 
several different pathways relevant to pathogenesis of 
Table 2 Mean ± SD values of various parameters with rituximab treatment
Mean/SD values 
of various parameters
Baseline Week 8 Week 16 Week 24
CRP mg/L 48,7 ± 49,5 24,4** ± 25,4 14,9** ± 14,7 12,1** ± 10,2
ESR mm/h 48,1 ± 27,2 37,5† ± 21,8 25,8** ± 12,7 23,8** ± 13,4
RF IU/ml 140 ± 498,8 61,8** ± 469,73 48,5** ± 39,35 41** ± 40,5
CCP U/ml 56 ± 44,1 49,8 ± 40,5 46,2 ± 39,3 42,2 ± 40,5
C3 mg/dl 136,3 ± 38,2 128,2 ± 33,18 118,4 ± 38,5 121,7 ± 28,8
C4 mg/dl 24,4 ± 10,1 23,1 ± 8,6 23 ± 7,2 22,5 ± 6,8
IgM mg/dl 164,2 ± 112,5 139,1 ± 94,9 116,4 ± 98,4 112,4 ± 55,1
IgA mg/dl 296,1 ± 155,2 275 ± 162,4 243,2 ± 119,1 235,8 ± 123,8
IgG mg/dl 1500,7 ± 513,1 1249,2 ± 353,5 1159 ± 311,2 1153,5 ± 286,3
HAQ 20 2,1 ± 0,42 1,6* ± 0,41 1,2* ± 0,42 1,1* ± 0,47
DAS-28 6,6 ± 0,78 5,69** ± 0,98 4,95* ± 0,98 4,42* ± 1,12
VAS 82,8 ± 11,5 65,7* ± 17,4 50,9* ± 14,4 39,7* ± 14
TJC 18,2 ± 7,2 14,3† ± 6,8 10,8** ± 6,3 8,5* ± 6
SJC 9,7 ± 2,8 7,4† ± 3,3 5,6* ± 2,3 4,6* ± 2,5
Notes: *P   0, 0001; **P   0, 01; †P   0, 05; P = not signiﬁ  cant.Biologics: Targets & Therapy 2008:2(4) 914
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Figure 1 ACR responses in patients with RA treated with rituximab.
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Figure 3 Reduction in RF and anti-CCP levels after rituximab treatment.
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Figure 2 Reduction in DAS28 and HAQ20 after therapy with rituximab.Biologics: Targets & Therapy 2008:2(4) 915
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inﬂ  ammatory arthritis. These pathways include production of 
auto antibodies such as RF and anti-CCP, T-cell activation, 
and production by macrophages proinﬂ  ammatory cytokines 
(Dorner and Burmeister 2003; Tuscano et al 2003).
In our study, the auto-antibodies proﬁ  le was different 
between RF and anti-CCP. RF decreased statistically sig-
niﬁ  cant and was correlated with the reduction of DAS-28 
and CRP, while anti-CCP did not correlate with the reduction 
of DAS-28 and CRP as a measure of disease activity. This 
observation suggests that RF is a better indicator of patient’s 
clinical and serological response after rituximab treatment 
than anti-CCP. As expected from the mechanism of rituximab 
action, treatment with this agent led to a rapid and complete 
depletion of CD20+ peripheral B cells. The CD20 antigen is 
not expressed on stem cells or plasma cells, so it is not sur-
prising that the mean levels of IgA, IgM, and IgG generally 
remained within the normal range throughout the 24 weeks. 
The prolonged depletion of CD20+ peripheral B cells in 
rituximab-treated patients raises the question of whether these 
patients may have great risk for severe infections, although 
the data from this and other studies (Fleischmann et al 2006; 
Keystone et al 2006) do not support this hypothesis, and only 
four patients had minor upper respiratory tract infections 
during follow up for 24 weeks. In conclusion, our results 
demonstrate that a single course of two 1000 mg infusion 
of rituximab given 2 weeks apart, in combination with base-
line DMARDs, produced signiﬁ  cant clinical and functional 
beneﬁ  ts at 24 weeks in patients with refractory RA in a real 
life setting outside from formal clinical trials.
Ongoing studies will continue to examine the long-term 
safety of rituximab in RA patients.
Conclusions
Treatment with rituximab was effective and well tolerated 
without major adverse events. Patient response to treat-
ment was independent to the presence of RF and anti-CCP 
antibodies. The decline of RF was correlated with the 
reduction of disease activity (DAS-28 and CRP); on the 
contrary, the anti-CCP titer was not statistical signiﬁ  cantly 
correlated to disease activity (DAS-28 and CRP). These 
observations suggest that RF is a better serological marker 
than anti-CCP for the evaluation of response to rituximab 
during follow-up.
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